Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Interest & Investment Income (2024 - 2025)

Evommune (EVMN) has disclosed Interest & Investment Income for 2 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 98.49% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.3 million for FY2025, 2.5% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.4 million at Evommune, up from $862000.0 in the prior quarter.
  • The five-year high for Interest & Investment Income was $1.4 million in Q4 2025, with the low at $618000.0 in Q3 2024.